Publications by authors named "BiXia Tang"

Claim this Profile
G
Genome Variation Map: a platform for the analysis and integration of genomic variation.
Xue Bai, Haixia Xie, Hong Luo, Siwei Ren, Bixia Tang

Nucleic Acids Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EWAS Open Platform 2026: a deeply integrated resource for epigenome-wide association studies.
Fei Yang, Zhuang Xiong, Wenting Zong, Demian Kong, Bixia Tang

Nucleic Acids Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AuraGenome: An LLM-Powered Framework for On-the-Fly Reusable and Scalable Circular Genome Visualizations.
Chi Zhang, Yu Dong, Yang Wang, Yuetong Han, Guihua Shan, Bixia Tang

IEEE Comput Graph Appl· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lineage-associated Human Divergently-paired Genes Exhibit Structural and Regulatory Characteristics.
Guangya Duan 段光亚, Sisi Zhang 张思思, Bixia Tang 唐碧霞, Jingfa Xiao 肖景发, Zhang Zhang 章张

Genomics Proteomics Bioinformatics· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TCR and BCR repertoire analysis reveals distinct signatures between benign and malignant ovarian tumors.
Zhonghuang Wang, Zhe Zhang, Dongli Zhao, Zhenglin Du, Bixia Tang

Front Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HiLand Resource: A Comprehensive Database of Highland Human Populations.
Weijie Zhang, Xiaoning Chen, Yanling Sun, Yibo Wang, Bixia Tang

Genomics Proteomics Bioinformatics· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in antibody-drug conjugates for urothelial carcinoma treatment.
Jinchang Wei, Bixia Tang, Xieqiao Yan, Juan Li, Li Zhou

Cancer Biol Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study.
Xieqiao Yan, Juan Li, Huayan Xu, Yiqiang Liu, Li Zhou, Bixia Tang

Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome diversity and signatures of natural selection in mainland Southeast Asia.
Yaoxi He, Xiaoming Zhang, Min-Sheng Peng, Yu-Chun Li, Kai Liu, Bixia Tang

Nature· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine learning-based prediction model for cognitive impairment risk in patients with chronic kidney disease.
Meng Cao, Bixia Tang, Liwei Yang, Jing Zeng

PLoS One· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma.
Jiaran Zhang, Huichun Tian, Lili Mao, Caili Li, Xiaoting Wei, Bixia Tang

Cancer Manag Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 Therapy.
Linzi Sun, Xiaoting Wei, Qian Zhao, Lili Mao, Xue Bai, Bixia Tang

J Extracell Vesicles· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy.
Siming Li, Jinchang Wei, Huayan Xu, Xiaowen Wu, Juan Li, Bixia Tang

World J Urol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predominance of hyperprogression in mucosal melanoma during anti-PD-1 monotherapy treatment.
Li Zhou, Min Cao, Haibin Zhu, Zhihong Chi, Chuanliang Cui, Bixia Tang

Oncologist· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma.
Bixia Tang, Jun Xiao, Zhihong Chi, Rong Duan, Chuanliang Cui

Oncologist· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights.
Xuan Wang, Hui Tian, Zhihong Chi, Lu Si, Xinan Sheng, Bixia Tang

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
iDog: a multi-omics resource for canids study.
Yanhu Liu, Yibo Wang, Jiani Sun, Demian Kong, Bowen Zhou, Bixia Tang

Nucleic Acids Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A machine learning-based model for predicting the risk of cognitive frailty in elderly patients on maintenance hemodialysis.
Meng Cao, Bixia Tang, Liwei Yang, Jing Zeng

Sci Rep· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial.
Jiayong Liu, Xuan Wang, Zhongwu Li, Shunyu Gao, Lili Mao, Bixia Tang

Signal Transduct Target Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Classification of Dog Breeds Using Convolutional Neural Network Models and Support Vector Machine.
Ying Cui, Bixia Tang, Gangao Wu, Lun Li, Xin Zhang

Bioengineering (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial.
Bixia Tang, Yu Chen, Yu Jiang, Meiyu Fang, Quanli Gao

J Immunother Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GenBase: A Nucleotide Sequence Database.
Congfan Bu, Xinchang Zheng, Xuetong Zhao, Tianyi Xu, Xue Bai, Bixia Tang

Genomics Proteomics Bioinformatics· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinoma.
Chuanliang Cui, Juan Li, Yue Yang, Lu Si, Zhihong Chi, Bixia Tang

Innovation (Camb)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep Attention Fusion Hashing (DAFH) Model for Medical Image Retrieval.
Gangao Wu, Enhui Jin, Yanling Sun, Bixia Tang, Wenming Zhao

Bioengineering (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plant genomic resources at National Genomics Data Center: assisting in data-driven breeding applications.
Dongmei Tian, Tianyi Xu, Hailong Kang, Hong Luo, Yanqing Wang, Bixia Tang

aBIOTECH· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis